Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2017 10:54

RNS Number : 7446Y
Faron Pharmaceuticals Oy
07 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

 

Legal & General Group Plc (L&G)

 

Legal & General (Unit Trust Managers) Limited (UTM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

03 March 2017

6. Date on which issuer notified:

07 March 2017

7. Threshold(s) that is/are crossed orreached:

 

UTM (Below 5%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

1,365,000.00

 Below 5%

-

 Below 5%

-

 Below 5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 UTM

(Below 5%)

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,565,000 - 5.64%= Total Position)

Legal & General (Unit Trust Managers) Limited (Below 5% = UTM)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

 

13. Additional information:

Notification using the total voting rights figure of  27,734,044

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGGFGNMGNZM
Date   Source Headline
18th Apr 20174:17 pmRNSPurchase of Shares
18th Apr 20177:00 amRNSCollaboration with Birmingham University
13th Apr 20171:43 pmRNSPurchase of Shares
4th Apr 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSFinal Results 2016
27th Mar 20179:23 amRNSHolding(s) in Company
21st Mar 201711:05 amRNSSecond Price Monitoring Extn
21st Mar 201711:00 amRNSPrice Monitoring Extension
7th Mar 201710:54 amRNSHolding(s) in Company
7th Mar 20177:00 amRNSNotice of Full Year Results
3rd Mar 201711:02 amRNSHolding(s) in Company
1st Mar 20172:05 pmRNSSecond Price Monitoring Extn
1st Mar 20172:00 pmRNSPrice Monitoring Extension
1st Mar 201711:35 amRNSResult of Placing & Subscription & Issue of Equity
28th Feb 20177:00 amRNSProposed Placing and Subscription
20th Feb 20177:00 amRNSFirst Patient Recruited in Phase II RAAA Study
9th Feb 20177:00 amRNSFaron update for 2017
9th Dec 20161:05 pmRNSNotification of Major Interest in Shares
9th Dec 20161:00 pmRNSNotification of Major Interest in Shares
5th Dec 20167:00 amRNSPDMR Shareholding
21st Nov 20167:00 amRNSGrant of options
31st Oct 20167:00 amRNSNew Application Accepted by Finnish Patent Office
24th Oct 20167:00 amRNSFirst patient recruited in Japanese Ph III trial
7th Oct 20161:41 pmRNSNotification of Major Interest in Shares
6th Oct 201610:00 amRNSNotification of Major Interest in Shares
5th Oct 20165:10 pmRNSNotification of Major Interest in Shares
26th Sep 20163:59 pmRNSDirector Dealing
21st Sep 201611:27 amRNSRaises £8.0 M through a Placing and Subscription
20th Sep 20167:00 amRNSProposed Placing & Subscription to raise £8M
5th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
10th Aug 20167:00 amRNSFaron Pharmaceuticals Notice of Interim Results
25th Jul 20167:00 amRNSFaron enters agreement with Abzena for Clevegen
22nd Jun 201612:00 pmRNSFaron to Present at Proactive Investors Forum
14th Jun 20167:00 amRNSFaron Provides Update at R&D Day
13th Jun 20167:00 amRNSFaron Licenses Traumakine Rights to Pharmbio Korea
26th May 201610:53 amRNSFaron Result of Annual General Meeting
26th May 20167:00 amRNSFaron Expands R&D Strategy for Clevegen
13th May 20167:00 amRNSFaron Pharmaceuticals Ltd to host an R&D Day
4th May 20167:00 amRNSNotice of AGM
3rd May 20167:00 amRNSFaron Appoints New Medical Director
22nd Apr 20167:00 amRNSFaron Appoints Panmure Gordon as Joint Broker
19th Apr 20167:00 amRNSFaron Files Two New Patents to Protect Clevegen
10th Mar 20167:00 amRNSAnnual Results for the year ended 31 December 2015
1st Mar 20167:00 amRNSFaron files patent application for Traumakine
10th Feb 20167:00 amRNSNotice of Preliminary Results
7th Jan 20167:00 amRNSTop-line results from Japanese study of Traumakine
29th Dec 20157:00 amRNSFirst Patient recruited in Phase III ARDS Study
21st Dec 20157:00 amRNSFaron Awarded ?1.5 million Tekes Funding
30th Nov 20157:00 amRNSKey Publication in Journal of Immunology
17th Nov 20157:30 amRNSAdmission to AIM and first day of dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.